Opening https://www.businesswire.com/news/home/20240416414460/en/IMFINZI%C2%AE-durvalumab-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-TOPAZ-1-Phase-III-trial